EA200501230A1 - Жидкие составы фактор некроза опухоли - связывающих белков - Google Patents

Жидкие составы фактор некроза опухоли - связывающих белков

Info

Publication number
EA200501230A1
EA200501230A1 EA200501230A EA200501230A EA200501230A1 EA 200501230 A1 EA200501230 A1 EA 200501230A1 EA 200501230 A EA200501230 A EA 200501230A EA 200501230 A EA200501230 A EA 200501230A EA 200501230 A1 EA200501230 A1 EA 200501230A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding proteins
necrosis factor
tumor necrosis
liquid compositions
binding protein
Prior art date
Application number
EA200501230A
Other languages
English (en)
Other versions
EA009079B1 (ru
Inventor
Фабрицио Самаритани
Алессандра Дель Рио
Рита Агостинетто
Original Assignee
Арес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арес Трейдинг С.А. filed Critical Арес Трейдинг С.А.
Publication of EA200501230A1 publication Critical patent/EA200501230A1/ru
Publication of EA009079B1 publication Critical patent/EA009079B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В изобретении описан стабильный фармацевтически приемлемый водный состав ФНО-связывающего белка, включающий ФНО-связывающий белок, буфер и изотонический агент.
EA200501230A 2003-02-28 2004-02-11 Жидкие составы фактор некроза опухоли-связывающих белков EA009079B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28
PCT/EP2004/050118 WO2004075918A1 (en) 2003-02-28 2004-02-11 Liquid formulations of tumor necrosis factor-binding proteins

Publications (2)

Publication Number Publication Date
EA200501230A1 true EA200501230A1 (ru) 2006-04-28
EA009079B1 EA009079B1 (ru) 2007-10-26

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501230A EA009079B1 (ru) 2003-02-28 2004-02-11 Жидкие составы фактор некроза опухоли-связывающих белков

Country Status (22)

Country Link
US (3) US8937045B2 (ru)
EP (1) EP1603596B1 (ru)
JP (1) JP4980048B2 (ru)
KR (1) KR20050105486A (ru)
CN (1) CN100563712C (ru)
AR (1) AR043418A1 (ru)
AT (1) ATE394123T1 (ru)
BR (1) BRPI0407649A (ru)
CA (1) CA2515539A1 (ru)
DE (1) DE602004013557D1 (ru)
EA (1) EA009079B1 (ru)
ES (1) ES2304602T3 (ru)
HK (1) HK1085677A1 (ru)
HR (1) HRP20050706A2 (ru)
IL (1) IL170414A (ru)
MX (1) MXPA05009135A (ru)
NO (1) NO20054440L (ru)
PL (1) PL213501B1 (ru)
RS (1) RS51041B (ru)
UA (1) UA82503C2 (ru)
WO (1) WO2004075918A1 (ru)
ZA (1) ZA200506504B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
ME02506B (me) 2010-11-11 2017-02-20 Abbvie Biotechnology Ltd VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
JP6220789B2 (ja) 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
EP4218937A3 (en) * 2011-10-31 2023-10-25 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
CA2878508A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
CN104902914B (zh) 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
WO2014064637A1 (en) 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of tnfr:fc fusion protein
WO2015198456A1 (ja) 2014-06-26 2015-12-30 丸石製薬株式会社 安定性を改善したロクロニウム製剤
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
ATE212231T1 (de) * 1995-07-14 2002-02-15 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
JP2000510113A (ja) 1996-05-08 2000-08-08 エフ・ホフマン―ラ ロシュ アーゲー ＴＮＦＲ―Ｉｇによる喘息の治療
CA2273850A1 (en) * 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
ES2618832T3 (es) * 2002-02-27 2017-06-22 Immunex Corporation Composición TNFR-FC estabilizada que comprende arginina

Also Published As

Publication number Publication date
HRP20050706A2 (en) 2005-12-31
EP1603596A1 (en) 2005-12-14
ZA200506504B (en) 2006-12-27
MXPA05009135A (es) 2005-10-20
KR20050105486A (ko) 2005-11-04
EP1603596B1 (en) 2008-05-07
UA82503C2 (ru) 2008-04-25
CN1774266A (zh) 2006-05-17
US9512215B2 (en) 2016-12-06
NO20054440L (no) 2005-09-26
IL170414A (en) 2009-11-18
JP4980048B2 (ja) 2012-07-18
US20170020960A1 (en) 2017-01-26
ATE394123T1 (de) 2008-05-15
CA2515539A1 (en) 2004-09-10
RS51041B (sr) 2010-10-31
CN100563712C (zh) 2009-12-02
DE602004013557D1 (de) 2008-06-19
US8937045B2 (en) 2015-01-20
RS20050662A (en) 2007-11-15
BRPI0407649A (pt) 2006-02-21
AR043418A1 (es) 2005-07-27
US20070053906A1 (en) 2007-03-08
EA009079B1 (ru) 2007-10-26
AU2004216483A1 (en) 2004-09-10
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
HK1085677A1 (en) 2006-09-01
JP2006519210A (ja) 2006-08-24
ES2304602T3 (es) 2008-10-16
US20150098950A1 (en) 2015-04-09
PL378290A1 (pl) 2006-03-20

Similar Documents

Publication Publication Date Title
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
NO20010062L (no) Bifenylsulfonamider som duale angiotensin-endotelin- reseptorantagonister
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
SG157952A1 (en) Small molecule antagonists of bcl-2 family proteins
EA200800233A1 (ru) Композиция иммуноконьюгата
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
SE0301653D0 (sv) Novel compounds
EA200701439A1 (ru) Pyy-агонисты и их применение
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CO5720212A1 (es) Composicion de anticuerpo her2
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
EA200201214A1 (ru) Замещенные тиоацетамиды
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
MEP20908A (en) Thienopyrazoles
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
EA200601855A1 (ru) Гербицидоактивные 3-амино-2-тиометилбензоилпиразолы
DK1622939T3 (da) Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
IL175646A0 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE391489T1 (de) Haarbehandlungszusammensetzungen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ TJ